Expression of epidermal growth factor receptor detected by cetuximab indicates its efficacy to inhibit in vitro and in vivo proliferation of colorectal cancer cells
Project/Area Number |
23791559
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Keio University |
Principal Investigator |
SHIGETA Kohei 慶應義塾大学, 医学部, 助教 (30528790)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2011: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 大腸癌 / 分子標的治療薬 / セツキシマブ |
Research Abstract |
Cetuximab is a monoclonal antibody of the IgG1 subclass that targets the human epidermal growth factor receptor (EGFR). We hypothesized that the expression levels of EGFR which can be detected by cetuximab itself may influence the inhibition of cell proli
|
Report
(3 results)
Research Products
(8 results)